← Back to guidelines
Oncology3 papers

Acral lentiginous melanoma, malignant

Last edited:

Epidemiology

Acral melanoma (AM) accounts for a disproportionately higher percentage of cases among individuals with darker skin tones, including those of African, Asian, and Hispanic descent [PMID:41650285].

Clinical Presentation

Clinically, AM typically presents as asymmetric brown macules with irregular borders and variable pigmentation [PMID:41650285].

Diagnosis

Although not required for diagnosis or staging protocols, Ki-67, a cell proliferation marker, can provide additional prognostic information beyond histopathological analysis [PMID:41861758].

A study identified 69 differentially expressed miRNAs in serum exosomes from patients with acral melanocytic tumors, suggesting these miRNAs could potentially aid in the early and non-invasive diagnosis of acral melanoma [PMID:42001282].

Differential Diagnosis

The research highlighted differential expression patterns of miRNAs, with 14 up-regulated and 55 down-regulated miRNAs, indicating these profiles could help distinguish between benign and malignant acral melanocytic tumors [PMID:42001282].

Management

Given that elevated Ki-67 indices predict poorer outcomes, incorporating Ki-67 assessment into follow-up protocols could inform more aggressive management approaches [PMID:41861758].

Prognosis & Follow-up

Elevated Ki-67 indices in acral cutaneous melanomas (ACM) correlate with unfavorable outcomes, suggesting its utility as a prognostic marker [PMID:41861758].

AM is associated with poorer prognosis and lower survival rates compared to non-AM melanomas, likely due to delayed diagnosis and greater tumor thickness at presentation [PMID:41650285].

Key Recommendations

Given the potential of exosomal miRNAs as stable biomarkers, future clinical studies are advised to validate their utility in routine diagnostic protocols for acral melanoma [PMID:42001282]. (Evidence: Expert opinion)

References

1 Asato MA, Contel IJ, Moraes Neto FA, Ocanha-Xavier JP, Oliveira NSC, Fung MA et al.. Ki-67 staining pattern as a prognostic biomarker for advanced acral melanoma. Anais brasileiros de dermatologia 2026. link 2 Russolillo JK, Schaedler A, Hsia B, Silberstein PT, Tauseef A, Torbenson E. Comprehensive Genomic Profiling of Acral Melanoma: Insights From the AACR Project GENIE Database. The American Journal of dermatopathology 2026. link 3 Zhu T, Wang J, Wang Y, Wen C, Han Y, Hu Y et al.. Differential expression analysis of serum exosome miRNAs in acral melanocytic tumor. Pakistan journal of pharmaceutical sciences 2026. link

Original source

  1. [1]
    Ki-67 staining pattern as a prognostic biomarker for advanced acral melanoma.Asato MA, Contel IJ, Moraes Neto FA, Ocanha-Xavier JP, Oliveira NSC, Fung MA et al. Anais brasileiros de dermatologia (2026)
  2. [2]
    Comprehensive Genomic Profiling of Acral Melanoma: Insights From the AACR Project GENIE Database.Russolillo JK, Schaedler A, Hsia B, Silberstein PT, Tauseef A, Torbenson E The American Journal of dermatopathology (2026)
  3. [3]
    Differential expression analysis of serum exosome miRNAs in acral melanocytic tumor.Zhu T, Wang J, Wang Y, Wen C, Han Y, Hu Y et al. Pakistan journal of pharmaceutical sciences (2026)

HemoChat

by SPINAI

Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

⚕ For clinical reference only. Not a substitute for professional judgment.

© 2026 HemoChat. All rights reserved.
Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG